Table 3. Associations between decreased expression of E-cadherin and clinicopathological features.
| Clinicopathological features | Pooled HR | 95% CI for HR | p value | I2 value (%) | Model | |
|---|---|---|---|---|---|---|
| Lower | Upper | |||||
| Age (≥ 50 vs. < 50) | 1.07 | 0.85 | 1.36 | 0.145 | 41.5 | Random |
| FIGO stage (III, IV vs. I, II) | 3.74 | 2.24 | 6.23 | 0.37 | 0 | Fixed |
| E-cadherin membranous staining (negative vs. positive) | 1.47 | 1.01 | 2.14 | 0.78 | 0 | Fixed |
| Pathologic grade (G3 vs. G1, G2) | 1.41 | 1.01 | 1.97 | 0.13 | 47 | Random |
| Residual tumor (<1cm vs. > 1cm) | 2.72 | 1.99 | 3.72 | 0.51 | 0 | Fixed |
| Surgery (suboptimal vs. optimal) | 3.21 | 1.19 | 8.67 | 0.074 | 68.7 | Random |
| Chemotherapy (non-paclitaxel vs. paclitaxel) | 1.31 | 0.31 | 5.57 | <0.01 | 90.4 | Random |
| Lymphatic metastasis (negative vs. positive) | 1.40 | 0.63 | 3.10 | 0.01 | 86.6 | Random |